Please confirm that you would like to log out of Medscape.
If you log out, you will be required to enter your username and password the next time you visit.
Log outCancel
Diacerein ointment, an investigational rhein prodrug for the treatment of epidermolysis bullosa, was granted FDA Rare Pediatric Disease and Fast Track development designation in 2018.
Topical glycopyrronium tosylate was recently FDA-approved to manage patients with primary axillary hyperhidrosis. Review the clinical trial results in this article.
Advances in immunotherapeutics in the last decade have drastically changed the outlook for patients with metastatic melanoma. Review the currently available immunotherapies in this update.
Review the many treatment options available for primary focal hyperhidrosis, including emerging procedures such as microwave thermolysis, focused ultrasound therapy, and surgical interventions.
